Antimalarial Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Malaria Type, By Region and Competition, 2020-2030F

Description

The Global Antimalarial Drugs Market was valued at USD 554.20 million in 2024 and is projected to reach USD 711.04 million by 2030, growing at a CAGR of 4.44%. With malaria remaining prevalent in regions like sub-Saharan Africa and parts of Asia, demand for effective treatments remains robust. Artemisinin-based combination therapies (ACTs) continue to lead the market due to their efficacy and established role in standard treatment protocols. The market is being further driven by increased investment in research and development aimed at addressing the rise in drug-resistant malaria strains. Innovations such as triple combination therapies, long-acting injectables, and improved formulations for children are being pursued to enhance effectiveness and adherence. While advancements continue, the market faces persistent challenges from evolving resistance patterns, highlighting the need for ongoing development of novel treatment approaches.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 554.20 Million
Market Size 2030	USD 711.04 Million
CAGR 2025-2030	4.44%
Fastest Growing Segment	Quinine
Largest Market	North America

Key Market Drivers

Growth in Healthcare Industry

The sustained expansion of the global healthcare industry-projected to surpass USD 4 trillion annually-is significantly bolstering the antimalarial drugs market. Pharmaceuticals and biotechnology contribute nearly USD 850 billion, supported by diagnostics and medical technology. In malaria-endemic regions such as Africa, Asia, and Latin America, increased public and private investment in healthcare infrastructure has enhanced access to diagnostics and treatments. This improved accessibility enables timely intervention, allowing for broader administration of antimalarial drugs and supporting continuous market growth.

Key Market Challenges

Inconsistency in Drug Supply

Supply inconsistency remains a major hurdle in the global antimalarial drugs market, especially in regions where malaria is most prevalent. Despite advancements in drug development and distribution frameworks, many affected areas still experience irregular access to essential medications. This issue is most acute in remote or low-income regions with fragile healthcare infrastructure. Key contributing factors include limited manufacturing capacity, inefficient procurement systems, and logistical obstacles that lead to delayed or insufficient supply. Seasonal fluctuations in malaria cases-often linked to monsoon or rainy seasons-further strain these underprepared supply chains. Inadequate inventory control and fragmented distribution networks can result in stockouts at critical points of care, ultimately disrupting treatment and increasing health risks.

Key Market Trends

Increased Focus on Herbal and Plant-Based Therapies

There is a growing trend toward the development and adoption of herbal and plant-based therapies in the antimalarial drugs market. Plant-derived compounds such as quinine, quinidine, and artemisinin remain pivotal in the fight against malaria. This shift is largely influenced by rising interest in natural and traditional treatments, particularly in regions where indigenous medicine is widely practiced. Concerns regarding side effects of synthetic drugs and the emergence of resistant malaria strains have prompted researchers and pharmaceutical firms to explore botanical alternatives. Artemisinin-extracted from sweet wormwood-serves as a cornerstone of ACTs and exemplifies the clinical success of plant-based remedies. Ongoing exploration of other medicinal plants, including neem and cinchona bark, continues to expand the pipeline of potential antimalarial agents derived from natural sources.

Key Market Players

Cipla Ltd
GlaxoSmithKline Plc
Ipca Laboratories Ltd.
Merck & Co., Inc
Novartis AG
Zydus Cadila
Sun Pharmaceutical Industries Ltd.
Strides Pharma Science Limited
Glenmark Pharmaceuticals Ltd.
Lincoln Pharmaceuticals Ltd.

Report Scope

In this report, the Global Antimalarial Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antimalarial Drugs Market, By Drug Type:

Quinine
Chloroquine
Proguanil
Amodiaquine
Mefloquine
Hydroxychloroquine
Pyrimethamine
Others

Antimalarial Drugs Market, By Malaria Type:

Plasmodium Falciparum
Plasmodium Malariae
Plasmodium Vivax
Plasmodium Ovale
Plasmodium Knowlesi

Antimalarial Drugs Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antimalarial Drugs Market.

Available Customizations

Global Antimalarial Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Antimalarial Drugs Market

5. Global Antimalarial Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Quinine, Chloroquine, Proguanil, Amodiaquine, Mefloquine, Hydroxychloroquine, Pyrimethamine, Others)
- 5.2.2. By Malaria Type (Plasmodium Falciparum, Plasmodium Malariae, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Knowlesi)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Antimalarial Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Malaria Type
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Antimalarial Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Type
    - 6.3.1.2.2. By Malaria Type
- 6.3.2. Mexico Antimalarial Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Type
    - 6.3.2.2.2. By Malaria Type
- 6.3.3. Canada Antimalarial Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Type
    - 6.3.3.2.2. By Malaria Type

7. Europe Antimalarial Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Malaria Type
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Antimalarial Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Type
    - 7.3.1.2.2. By Malaria Type
- 7.3.2. Germany Antimalarial Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Type
    - 7.3.2.2.2. By Malaria Type
- 7.3.3. United Kingdom Antimalarial Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Type
    - 7.3.3.2.2. By Malaria Type
- 7.3.4. Italy Antimalarial Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Type
    - 7.3.4.2.2. By Malaria Type
- 7.3.5. Spain Antimalarial Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Type
    - 7.3.5.2.2. By Malaria Type

8. Asia Pacific Antimalarial Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Malaria Type
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Antimalarial Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Type
    - 8.3.1.2.2. By Malaria Type
- 8.3.2. India Antimalarial Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Type
    - 8.3.2.2.2. By Malaria Type
- 8.3.3. South Korea Antimalarial Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Type
    - 8.3.3.2.2. By Malaria Type
- 8.3.4. Japan Antimalarial Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Type
    - 8.3.4.2.2. By Malaria Type
- 8.3.5. Australia Antimalarial Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Type
    - 8.3.5.2.2. By Malaria Type

9. South America Antimalarial Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Malaria Type
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Antimalarial Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Type
    - 9.3.1.2.2. By Malaria Type
- 9.3.2. Argentina Antimalarial Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Type
    - 9.3.2.2.2. By Malaria Type
- 9.3.3. Colombia Antimalarial Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Type
    - 9.3.3.2.2. By Malaria Type

10. Middle East and Africa Antimalarial Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Malaria Type
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Antimalarial Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Type
    - 10.3.1.2.2. By Malaria Type
- 10.3.2. Saudi Arabia Antimalarial Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Type
    - 10.3.2.2.2. By Malaria Type
- 10.3.3. UAE Antimalarial Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Type
    - 10.3.3.2.2. By Malaria Type

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Antimalarial Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products

16. Competitive Landscape

16.1. Cipla Ltd
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. GlaxoSmithKline Plc
16.3. Ipca Laboratories Ltd.
16.4. Merck & Co., Inc
16.5. Novartis AG
16.6. Zydus Cadila
16.7. Sun Pharmaceutical Industries Ltd.
16.8. Strides Pharma Science Limited
16.9. Glenmark Pharmaceuticals Ltd.
16.10. Lincoln Pharmaceuticals Ltd.